FDA DEVICE FACTS
QIAstat-Dx BCID GPF Plus AMR Panel
QIAGEN GmbH
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The QIAstat-Dx BCID GPF Plus AMR Panel is a qualitative multiplexed nucleic acid real-time PCR-based in vitro diagnostic test intended for use with QIAstat-Dx Analyzer 2.0. The QIAstat-Dx BCID GPF Plus AMR Panel is capable of simultaneous detection and identification of multiple gram-positive bacterial and fungal pathogens and selected genetic determinants associated with antimicrobial resistance. Additionally, the QIAstat-Dx BCID GPF Plus AMR Panel is capable of detecting a wide variety of gram-negative bacteria (Pan Gram Negative assay). The QIAstat-Dx BCID GPF Plus AMR Panel is intended for use in positive blood culture samples from patients with blood stream infections identified via Gram stain to contain gram-positive bacteria or fungi. The following gram-positive bacteria are identified and differentiated using the QIAstat-Dx BCID GPF Plus AMR Panel:
• Bacillus cereus group
• Corynebacterium
• Enterococcus faecalis
• Enterococcus faecium
• Listeria monocytogenes
• Micrococcus spp.
• Staphylococcus aureus
• Staphylococcus epidermidis
• Staphylococcus lugdunensis
• S. capitis/ S. hominis
• Streptococcus agalactiae
• Streptococcus anginosus group
• Streptococcus pneumoniae
• Streptococcus pyogenes The following fungi are identified and differentiated using the QIAstat-Dx BCID GPF Plus AMR Panel:
• Cryptococcus neoformans/gattii
• Fusarium
• Candida auris The QIAstat-Dx BCID GPF Plus AMR Panel also contains targets designed to detect a broad range of organisms with a potentially misleading Gram stain result or organisms that may be missed by Gram staining altogether, for example in the case of co-infections. These include:
• A broad Pan Gram Negative assay
• Candida Group 1: (detects but does not differentiate 6 species) o Candida albicans o Candida tropicalis o Candida dubliniensis o Candida famata o Candida guilliermondii o Candida kefyr
• Candida Group 2: (detects but does not differentiate 4 species) o Candida glabrata o Candida krusei o Candida parapsilosis o Candida lusitaniae The QIAstat-Dx BCID GPF Plus AMR Panel contains assays for the detection of the following genetic determinants associated with resistance to antimicrobial agents:
• aac(6')-aph(2'')
• cfr
• ermA
• ermC
• mecA
• mecC
• tetK
• tetM
• vanA
• vanB The QIAstat-Dx BCID GPF Plus AMR Panel contains assays for the detection of genetic determinants associated with resistance to gentamicin/tobramycin/kanamycin (aac(6')- aph(2''))), PhLOPSA multi-class resistance phenotype (cfr), erythromycin (ermA and ermC), methicillin (mecA and mecC), tetracycline (tetK and tetM) and vancomycin (vanA and vanB). The antimicrobial resistance gene detected may or may not be associated with the agent responsible for disease. Negative results for certain antimicrobial resistance assays do not indicate susceptibility, as multiple mechanisms of resistance exist. The test is performed on blood culture samples identified as positive by a continuous monitoring blood culture system and gram-positive bacteria or fungi as determined by Gram stain. The QIAstat-Dx BCID GPF Plus AMR Panel is intended as an aid in diagnosis of bloodstream infections identifying specific pathogens and genetic determinants associated with resistance. Results should be used in conjunction with other clinical or laboratory information, e.g., Gram stain results. Sub-culturing of positive blood cultures is necessary for identification of organisms not detected by QIAstat-Dx BCID GPF Plus AMR Panel and susceptibility testing. Results should not be used as the sole basis for diagnosis, treatment, or other patient management decisions. Negative results do not preclude the presence of pathogens that are not detected by this test. Positive QIAstat-Dx BCID GPF Plus AMR results do not rule out infection or co-infection with organisms not included in the QIAstat-Dx BCID GPF Plus AMR Panel.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。